The introduction of next-generation sequencing (NGS) fundamentally changed how we approach scientific and diagnostic issues. Next-generation sequencing’s potential to produce large amounts of sequence data for a relatively low price led to a series of groundbreaking discoveries and ushered the field of genomics into a new era. Third-generation sequencing further have revolutionized the detection of genetic mutations owing to the single-molecule real-time (SMRT) technology.
The combination of six Illumina NovaSeq 6000 and the NovaSeq X Plus sequencing systems for high-throughput sequencing and PacBio’s Sequell IIe for high-quality long-read sequencing, provides a wide spectrum of sequencing applications for research projects and pharma studies.
CeGaT has specialized in the use of NGS since its foundation. We continuously invest in the newest technologies to aim for the most accurate and reliable results for our customers. Meanwhile we can offer our customers third-generation sequencing (TGS) on the PacBio sequencing platform. Our profound diagnostic knowledge and bioinformatic expertise complements the state-of-the-art lab platforms and sequencing technology. We offer the knowledge, the latest technology and award-winning service for your projects.
Our team has a substantial experience with human and other mammalian samples and a wide range of expertise in the processing of plant samples in addition to microbial samples.
Based on many years of using NGS technology, we have gained great expertise in high-throughput technology for processing thousands of samples. Our laboratories are equipped with liquid-handling workstation platforms from Hamilton. These platforms can be individually programmed allowing specific adaptations of our protocols based on your requirements.
The multiplexing strategy we have established in our laboratory allows the sequencing of hundreds of samples in one sequencing run, or even in one lane, and therefore represents true high-throughput sequencing.
We would be happy to demonstrate the feasibility of your high-throughput projects in a pilot study.